原著
First Author
Ratio of LDL- to HDL-associated platelet-activating factor acetylhydrolase may be a marker of inflammation in patients with paroxysmal atrial fibrillation.
Circ J. (2007, 71(2): 214-219)
Okamura, K. Miura, S. Zhang, B. Uehara, Y. Matsuo, K. Kumagai, K. Saku K.
Anti-hypertensive action and safety of candesartan / Hydrochlorothiazid combined drug in uncontrolled hypertensive patients: A prospective multicenter observational study (CHAT-E study)
Therapeutic Research (2015, 36(5): 439-448)
Okamura, K. Urata, H. Chikushi Anti-Hypertension Trial-Ecard (CHAT-E)
Prevalence and Characteristics of Treatment-Resistant Hypertension among Hypertensive Japanese Outpatients.
International Journal of Clinical Medicine (2015, 6: 623-634)
Okamura, K. Urata, H.
Heart Rate and Blood Pressure Changes in Four Healthy Volunteers During Commercial Flight
Therapeutic Research (2016, 37(12): 1167-1174)
Okamura, K, Okuda, T. Hiratsuka, Y. Shigekane, Y. Saruwatari, K. Urata, H.
Prospective direct comparison of antihypertensive effect and safety between high-dose amlodipine or indapamide in hypertensive patients uncontrolled by standard doses of angiotensin receptor blockers and amlodipine.
Clin Exp Hypertens. (2018, 40(2): 99-106)
Okamura, K. Shirai, K. Totake, N. Okuda, T. Urata, H.
Positive correlation between blood pressure or heart rate and chymase-dependent angiotensin II-forming activity in circulating mononuclear leukocytes measured by new ELISA.
Clin Exp Hypertens. (2018,40(2): 112-117)
Okamura, K. Okuda, T. Shirai, K. Urata, H.
The Prevalence of Japanese Outpatients with Hypertension Who Meet the Definition of Treatment Resistant Hypertension and Are Eligible for Enrolment in Clinical Trials of Endovascular Ultrasound Renal Denervation.
Intern Med. (2018, 57(1): 1-12)
Okamura, K. Shirai, K. Okuda, T. Urata, H.
Improvement of Diurnal Blood Pressure Variation by Azilsartan.
J Clin Med Res. (2018, 10(1): 41-49)
Okamura, K. Shirai, K. Okuda, T. Urata, H.
Prospective single-arm observational study of human chymase inhibitor Polygonum hydropiper L in subjects with hypertension.
Clin Exp Hypertens. (2018, 23: 1-9)
Okamura, K. Kuroda, R. Nagata, K. Urata, H.
Investigation of a Dipeptidyl Peptidase-4 Inhibitor/Thiazolidinedione Combination Drug for Patients With Type 2 Diabetes and Poor Glycemic Control: Difficulty With Patient Enrollment.
J Clin Med Res. (2019, 11(2): 89-97)
Okamura, K. Shirai, K. Miyazaki, M. Okuda, T. Takamiya, Y. Goto, M. Urata, H.
Increase of chymase-dependent angiotensin II-forming activity in circulating mononuclear leukocytes after acute myocardial infarction chymase activity after acute myocardial infarction.
Heart Vessels. 2019 Jul;34(7):1148-1157.
Okamura, K. Okuda, T. Shirai, K. Urata, H.
High Fib4 index in patients with suspected NASH is associated with elevation of chymase-dependent angiotensin II-forming activity in circulating mononuclear leucocytes.
Heart Vessels. 2019 Sep;34(9):1559-1569.
Okamura, K. Okuda, T. Takamiya, Y. Shirai, K. Urata, H.
First Author以外
Combined treatment with statin and angiotensin-receptor blocker after stenting as a useful strategy for prevention of coronary restenosis.
J Cardiol. (2005, 45(3):107-113)
Nishikawa, H. Miura, S. Shimomura, H. Tsujita, K. Okamura, K. Zhang, B. Iwata, A. Shirai, K. Matsuo, K. Arai, H. Saku, K.
アゼルニジピンのLDLに対する抗酸化作用 キャピラリー電気泳動法による評価Prog.Med. (2006, 26(7): 1661-1664)
谷川宏之, 三浦伸一郎, 岡村圭祐, 西川宏明, 上原吉就, 張波, 朔啓二郎
冠攣縮性狭心症患者の長期予後に及ぼすCa拮抗薬と硝酸薬併用の効果
Prog.Med. (2009, 29(3): 831-837)
三好恵、井上裕紀子、児玉直、角俊一郎、岡村圭祐、新村英也、安藤知恵、 山之内良雄、浦田秀則
Additive antihypertensive and antihypertrophic effects of long-acting Ca blockers in uncontrolled hypertensive patients with angiotensin-receptor blocker based treatment
Int Heart J (2009, 50(5): 555-570)
Kodama, S. Inoue, Y. Miyoshi, K. Sumi, S. Okamura, K. Tojo, H. Ando, C. Niimura, H. Tsuchiya, Y. Mihara, H. Yamanouchi, Y. Urata, H.
Beneficial effect of combination therapy comprising angiotensin Ⅱ receptor blocker plus calcium channel blocker on plasma adiponectin levels
Clin Exp Hypertension (2010, 32(1): 21-28)
Inoue, Y. Kakuma, T. Nonaka, Y. Sumi, S. Okamura, K. Kodama, S. Ando, C. Niimura, H. Miyoshi, K. Tsuchiya, Y. Yamanouchi, Y. Urata, H.
管理不良高血圧症例でのイルベサルタンの有効降圧と安全性 多施設共同前向き観察研究CHAT-A1y (Chikushi Anti-hypertension Trial-Avapro)
血圧 (2012, 19(10): 912-922)
松本研三, 角俊一郎, 高宮陽介, 岡村圭祐, 森憲, 北島研, 久保田和充, 東條秀明, 浦田秀則
Differential Action of Four Long Acting Calcium Channel Blockers on Heart Rate and Renal Function
Therapeutic Research (2013, 34(1): 93-104)
Tojo, H. Sumi, S. Okuda, T. Arimura, T. Okamura, K. Matsumoto, K. Takamiya, Y. Mitsutake, R. Kitajima, K. Mori, K. Saku, K. Urata, H.
Effect of Angiotensin-Converting Enzyme Inhibitor/Calcium Antagonist Combination Therapy on Renal Function in Hypertensive Patients With Chronic Kidney Disease: Chikushi Anti-Hypertension Trial – Benidipine and Perindopril.
J Clin Med Res. (2018, 10(2): 117-124)
Okuda, T. Okamura, K. Shirai, K. Urata, H.
Association between medication adherence and illness perceptions in atrial fibrillation patients treated with direct oral anticoagulants: An observational cross-sectional pilot study.
PLoS One. 2018 Sep 28;13(9)
Miyazaki, M. Nakashima, A. Nakamura, Y. Sakamoto, Y. Matsuo, K. Goto, M. Uchiyama, M. Okamura, K. Mitsutake, R. Urata, H. Kamimura, H. Imakyure, O.
Multicenter prospective observational study of teneligliptin, a selective dipeptidyl peptidase-4 inhibitor, in patients with poorly controlled type 2 diabetes: Focus on glycemic control, hypotensive effect, and safety Chikushi Anti-Diabetes Mellitus Trial-Teneligliptin (CHAT-T).
Clin Exp Hypertens. 2019 Apr 11:1-8.
Takamiya, Y. Okamura, K. Shirai, K. Okuda, T. Kobayashi, K. Urata, H.